Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Equity Average (2020 - 2025)

Historic Equity Average for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$10.1 million.

  • Xeris Biopharma Holdings' Equity Average rose 5764.46% to -$10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year increase of 5764.46%. This contributed to the annual value of -$18.2 million for FY2024, which is 19477.15% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Equity Average is -$10.1 million, which was up 5764.46% from -$27.2 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Equity Average peaked at $95.8 million during Q1 2022, and registered a low of -$32.4 million during Q1 2025.
  • For the 5-year period, Xeris Biopharma Holdings' Equity Average averaged around $16.5 million, with its median value being $3.6 million (2023).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Equity Average soared by 9288.11% in 2021 and then tumbled by 188621.87% in 2024.
  • Xeris Biopharma Holdings' Equity Average (Quarter) stood at $46.4 million in 2021, then grew by 8.04% to $50.1 million in 2022, then crashed by 102.91% to -$1.5 million in 2023, then tumbled by 1886.22% to -$29.0 million in 2024, then skyrocketed by 65.2% to -$10.1 million in 2025.
  • Its Equity Average stands at -$10.1 million for Q3 2025, versus -$27.2 million for Q2 2025 and -$32.4 million for Q1 2025.